Bright Minds Biosciences (DRUG) vs Eupraxia Pharmaceuticals (EPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eupraxia Pharmaceuticals (EPRX) has outperformed Bright Minds Biosciences (DRUG) over the past year, gaining 23.3% versus a loss of 5.8%. Bright Minds Biosciences is the larger company by market cap ($512.9 million vs $500.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRUG | EPRX |
|---|---|---|
| Share price | $52.00 | $7.57 |
| Market cap | $512.93M | $500.18M |
| 1-day change | 0.00% | -2.70% |
| YTD return | -33.37% | +0.26% |
| 1-year return | -5.80% | +23.29% |
| 5-year return | +39.97% | — |
| EPS (TTM) | $-2.05 | $-1.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $123.75 | $9.32 |
| 52-week low | $47.23 | $5.25 |
| Distance from 52-week high | -57.98% | -18.78% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +192.25% | +115.98% |
| Average volume | 159.01K | 575.10K |
| Shares outstanding | 9.86M | 66.07M |
| Employees | 26 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EPRX has outperformed DRUG by 29.1 percentage points over the past year.
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
About Eupraxia Pharmaceuticals
EPRX stock →Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Health Care · Pharmaceuticals and Biotechnology · 49 employees
DRUG vs EPRX FAQ
Which is bigger, Bright Minds Biosciences or Eupraxia Pharmaceuticals?
Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $512.93M compared with $500.18M for Eupraxia Pharmaceuticals (EPRX).
Which stock has performed better over the past year, DRUG or EPRX?
EPRX returned +23.29% over the past 12 months, compared with -5.80% for DRUG (price return, excluding dividends). Past performance does not predict future results.
Are Bright Minds Biosciences and Eupraxia Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Bright Minds Biosciences and Pharmaceuticals and Biotechnology for Eupraxia Pharmaceuticals.